FDA ACTIONS

FDA recommending 3 user-fee programs to speed drugs to market

FDA has completed its recommendations to Congress for 3 user-fee programs that will help speed safe and effective drugs and lower-cost generic drug and biosimilar biological products to patients. » More

Voraxaze approved for treating patients with toxic methotrexate levels

FDA approved glucarpidase (Voraxaze, BTG International) to treat patients with toxic levels of methotrexate in their blood because of kidney failure. » More

RCC agent earns positive review from FDA committee

The FDA’s Oncologic Drugs Advisory Committee voted unanimously 13 to 0 that data for axitinib support a favorable benefit/risk profile for the treatment of patients with advanced renal cell carcinoma after failure of a first-line systemic therapy. » More

CONTINUING EDUCATION

Cardiometabolic disease: The pharmacist’s tools for managing dyslipidemia and hypertension

Also known as syndrome X or metabolic syndrome, this condition can lead to diabetes, hypertension, and cardiovascular disease. For patients, pharmacists are an ideal source of information and support. Earn up to 2 CPE credits. » Click here to login and take the exams.

CLINICAL NEWS

ACP Foundation hopes tools can help prevent strokes in patients with atrial fibrillation

The ACP Foundation recently published a 31-page primer, Initiative on Atrial Fibrillation and Stroke Prevention, in the hopes of improving the care of patients with atrial fibrillation within health systems. » More

Varicella vaccination program cuts infection rate in infants

The U.S. varicella vaccination program has substantial indirect benefits for infants, who are not eligible to receive the vaccine, a recent report from the Centers for Disease Control and Prevention shows. » More

MEDICATION SAFETY

New data: ADT does not increase cardiovascular death risk

Contrary to the conclusions of recent research, androgen deprivation therapy does not appear to raise the risk of fatal heart attacks in men being treated for prostate cancer, results from a multicenter study indicate. » More

Confirm your
e-newsletter subscription click here.

To ensure future delivery of email newsletters from Drug Topics please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff

Voices

•	Anticoagulation update
•	JP at Large
•	View from the Zoo
•	Viewpoints
•	Regulatory & Legal

Meetings & Events

Digital Edition

•	View current edition

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.